Energy News Portal

Sustainable

GSK lung cancer drug gets speedy approval following $10.6B deal

Source: BioPharma Dive - Latest News

The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.

View Original Coverage